Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trail to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for Treatment of Acute Migraine in Sumatriptan Non-Responders.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Rizatriptan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Merck & Co; Organon
- 24 Jun 2010 Results have been presented in an abstract at the 52nd meeting of the American Headache Society.
- 26 Jan 2010 Actual patient number (109) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.